It has been hypothesised that V600EBRAF mutation and loss of CDX2, which are significantly associated, might cooperate in promoting CRC tumorigenesis.8,9 Dalerba et al. demonstrated that loss of CDX2 expression may confer poor prognosis to stage II-III CRC patients.10 Notwithstanding, no or limited information regarding the relative impact of BRAF mutations and other prognostic features were available.11 This evidence concerns the gene CDX2 and colorectal carcinoma.